Abstract
Alzheimer disease (AD) is the most common form of dementia in the elderly and the number of individuals developing the disease is rapidly rising. Interventions focused on reducing beta-amyloid (Aβ), a component of senile plaques within the AD brain offer a promising approach to prevent or slow disease progression. In this review, we describe the immune system and cognitive and neurobiological features of a natural model of human brain aging, the beagle. The immune system of dogs shares many features of the human immune system, including developmental and aging characteristics. Further, dogs naturally accumulate human sequence Aβ as they age, which coincides with declines in learning and memory. A longitudinal study (∼2 years) of the response of aged beagles to vaccination with fibrillar Aβ1-42 indicated that despite significant clearance of Aβ, there were limited benefits in cognitive function. However, there was evidence for maintenance of executive function over time. These results are strikingly similar to reports of human clinical immunotherapy trials. We propose that the canine model complements existing animal models and will be helpful in developing new vaccine approaches to slowing or preventing Aβ pathology that can be translated to human clinical trials.
CNS & Neurological Disorders - Drug Targets
Title: Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle
Volume: 8 Issue: 2
Author(s): Vitaly Vasilevko and Elizabeth Head
Affiliation:
Abstract: Alzheimer disease (AD) is the most common form of dementia in the elderly and the number of individuals developing the disease is rapidly rising. Interventions focused on reducing beta-amyloid (Aβ), a component of senile plaques within the AD brain offer a promising approach to prevent or slow disease progression. In this review, we describe the immune system and cognitive and neurobiological features of a natural model of human brain aging, the beagle. The immune system of dogs shares many features of the human immune system, including developmental and aging characteristics. Further, dogs naturally accumulate human sequence Aβ as they age, which coincides with declines in learning and memory. A longitudinal study (∼2 years) of the response of aged beagles to vaccination with fibrillar Aβ1-42 indicated that despite significant clearance of Aβ, there were limited benefits in cognitive function. However, there was evidence for maintenance of executive function over time. These results are strikingly similar to reports of human clinical immunotherapy trials. We propose that the canine model complements existing animal models and will be helpful in developing new vaccine approaches to slowing or preventing Aβ pathology that can be translated to human clinical trials.
Export Options
About this article
Cite this article as:
Vasilevko Vitaly and Head Elizabeth, Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle, CNS & Neurological Disorders - Drug Targets 2009; 8 (2) . https://dx.doi.org/10.2174/187152709787847333
DOI https://dx.doi.org/10.2174/187152709787847333 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Nanoparticulate Carrier Mediated Intranasal Delivery of Insulin for the Restoration of Memory Signaling in Alzheimer’s Disease
Current Nanoscience Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Recent Advances in Delivery Through the Blood-Brain Barrier
Current Topics in Medicinal Chemistry Association of Dietary Prebiotic Consumption with Reduced Risk of Alzheimer’s Disease in a Multiethnic Population
Current Alzheimer Research The Role of miR-124 in Drosophila Alzheimer's Disease Model by Targeting Delta in Notch Signaling Pathway
Current Molecular Medicine A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein
Current Alzheimer Research Antidepressant Related Movement Disorders in the Elderly
Current Psychiatry Reviews Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Editorial [Hot topic: Inflammation, Immunity, and Alzheimers Disease (Guest Editor: Terrence Town)]
CNS & Neurological Disorders - Drug Targets Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease
Current Alzheimer Research Parkinsons Disease Dementia
Current Psychiatry Reviews In Vivo Application of beta Amyloid Oligomers: A Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches
Current Pharmaceutical Design N-alkylated Tacrine Derivatives as Potential Agents in Alzheimer’s Disease Therapy
Current Alzheimer Research Structure-Activity Relationship Studies: M2 and CCR5 Receptor Antagonists
Current Topics in Medicinal Chemistry Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science Current Trends in the Animal Models for Screening of Nootropic Agents: A Systematic Review
Current Reviews in Clinical and Experimental Pharmacology Does the Cholinesterase Inhibitor, Donepezil, Benefit Both Declarative and Non-Declarative Processes in Mild to Moderate Alzheimers Disease?
Current Alzheimer Research